Recent Advances in Renal Denervation Therapy and Novel Applications of High-Intensity Focused Ultrasound.

Publisher: Hindawi Country of Publication: England NLM ID: 101319630 Publication Model: eCollection Cited Medium: Internet ISSN: 1755-5922 (Electronic) Linking ISSN: 17555914 NLM ISO Abbreviation: Cardiovasc Ther Subsets: MEDLINE

Publication: 2019- : [London, United Kingdom] : Hindawi
Original Publication: Oxford : Wiley-Blackwell, c2008-c2018.

Kidney*/innervation ; Kidney*/blood supply ; Hypertension*/physiopathology ; Hypertension*/surgery ; Hypertension*/diagnosis ; Hypertension*/therapy ; High-Intensity Focused Ultrasound Ablation*/adverse effects ; Blood Pressure*/drug effects ; Sympathectomy*/adverse effects ; Sympathectomy*/methods ; Renal Artery*/innervation; Humans ; Treatment Outcome ; Animals ; Antihypertensive Agents/therapeutic use

Competing Interests: The authors declare no conflicts of interest.
Hypertension constitutes a major risk factor for cardiovascular diseases. Globally, the management and control of hypertension remain suboptimal. At present, pharmacological intervention is a critical strategy for patients with hypertension to achieve blood pressure regulation. Nevertheless, inadequate adherence to prescribed medication significantly impedes effective blood pressure control. Renal denervation (RDN) has emerged as a minimally invasive intervention that has the potential to achieve long-term reduction in blood pressure. Many preclinical and clinical trials have validated the effects of RDN. While trials such as SYMPLICITY HTN-3 raised questions about the efficacy of RDN, the majority of subsequent clinical trials have demonstrated benefits in patients with resistant hypertension. Presently, traditional RDN therapy is characterized by invasiveness and technical complexity, so the utilization of noninvasive high-intensity focused ultrasound (HIFU) has been incorporated into RDN procedures. This review is aimed at consolidating data on the efficacy and safety of various RDN modalities, examining the implementation of noninvasive HIFU in RDN practices, and suggesting potential avenues for future advancements and opportunities.
(Copyright © 2025 JunHao Wang et al. Cardiovascular Therapeutics published by John Wiley & Sons Ltd.)

Lancet. 2017 Nov 11;390(10108):2160-2170. (PMID: 28859944)
Sensors (Basel). 2023 Apr 03;23(7):. (PMID: 37050766)
Eur Heart J. 2017 Jan 7;38(2):93-100. (PMID: 28158510)
N Engl J Med. 2014 Apr 10;370(15):1393-401. (PMID: 24678939)
J Hypertens. 2024 Jan 1;42(1):23-49. (PMID: 37712135)
J Cardiovasc Transl Res. 2023 Apr;16(2):358-370. (PMID: 36042146)
Minerva Cardiol Angiol. 2024 Aug;72(4):313-328. (PMID: 38535984)
Blood Press. 2017 Dec;26(6):366-380. (PMID: 28830251)
EClinicalMedicine. 2024 May 07;72:102626. (PMID: 38756107)
J Neural Eng. 2023 Nov 09;20(6):. (PMID: 37918024)
J Hypertens. 2022 Oct 1;40(10):1859-1875. (PMID: 36052518)
Integr Blood Press Control. 2023 Sep 07;16:59-70. (PMID: 37701066)
Int J Hyperthermia. 2016 Aug;32(5):569-82. (PMID: 27145871)
Lancet. 2021 Sep 11;398(10304):957-980. (PMID: 34450083)
Am Heart J. 2024 Mar;269:108-117. (PMID: 38128897)
Lancet. 2018 Jun 9;391(10137):2335-2345. (PMID: 29803590)
J Ther Ultrasound. 2016 Feb 03;4:3. (PMID: 26848390)
Lancet. 2020 May 2;395(10234):1444-1451. (PMID: 32234534)
Blood Press. 2018 Aug;27(4):185-187. (PMID: 29936868)
Front Cardiovasc Med. 2021 Oct 14;8:739560. (PMID: 34722673)
J Hypertens. 2021 Sep 1;39(9):1733-1741. (PMID: 34261957)
Circ Res. 2015 Mar 13;116(6):1074-95. (PMID: 25767291)
Hypertension. 2019 Jul;74(1):35-46. (PMID: 31132956)
Lancet. 2014 Feb 15;383(9917):622-9. (PMID: 24210779)
Circulation. 2018 May 29;137(22):2344-2356. (PMID: 29449338)
Eur Heart J. 2019 Nov 1;40(42):3474-3482. (PMID: 30907413)
J Hypertens. 2023 Dec 1;41(12):1874-2071. (PMID: 37345492)
Curr Hypertens Rep. 2016 Jun;18(6):48. (PMID: 27137523)
Vasc Health Risk Manag. 2022 May 13;18:375-386. (PMID: 35592729)
Hypertension. 2015 Oct;66(4):e22-5. (PMID: 26238444)
Ann Anat. 2016 Mar;204:71-9. (PMID: 26617159)
Lancet. 2018 Jun 9;391(10137):2346-2355. (PMID: 29803589)
AJR Am J Roentgenol. 2010 Sep;195(3):W245-52. (PMID: 20729423)
Catheter Cardiovasc Interv. 2024 Jul;104(1):34-43. (PMID: 38713867)
Front Cardiovasc Med. 2023 Jun 19;10:1210801. (PMID: 37404730)
Eur Heart J. 2015 Jan 21;36(4):219-27. (PMID: 25400162)
Lancet. 2009 Apr 11;373(9671):1275-81. (PMID: 19332353)
J Am Coll Cardiol. 2013 May 28;61(21):2185-92. (PMID: 23541964)
Hypertension. 2018 Jun;71(6):e13-e115. (PMID: 29133356)
Eur Heart J. 2023 Apr 17;44(15):1313-1330. (PMID: 36790101)
Lancet. 2010 Dec 4;376(9756):1903-9. (PMID: 21093036)
J Hypertens. 2018 Dec;36(12):2284-2309. (PMID: 30379783)
EuroIntervention. 2020 May 20;16(1):89-96. (PMID: 32038027)
J Am Coll Cardiol. 2019 Jun 18;73(23):3006-3017. (PMID: 31196459)
J Ultrasound Med. 2012 Apr;31(4):623-34. (PMID: 22441920)
Curr Probl Cardiol. 2024 Feb;49(2):102196. (PMID: 37952794)
Curr Probl Cardiol. 2021 Mar;46(3):100598. (PMID: 32448758)
Lancet. 2021 Jun 26;397(10293):2476-2486. (PMID: 34010611)
J Control Release. 2024 Aug;372:194-208. (PMID: 38897294)
J Am Coll Cardiol. 2014 Aug 19;64(7):644-6. (PMID: 25125293)
Lancet. 2022 Apr 9;399(10333):1401-1410. (PMID: 35390320)
J Hypertens. 2018 Mar;36(3):680-689. (PMID: 29035942)

0 (Antihypertensive Agents)

Date Created: 20250908 Date Completed: 20250908 Latest Revision: 20250910

20250910

PMC12413941

10.1155/cdr/6692871

40919414